Clinical Cancer Research, Vol 3, Issue 10 1699-1706, Copyright © 1997 by American Association for Cancer Research

ARTICLES

MYCN protein expression as a predictor of neuroblastoma prognosis

HS Chan, BL Gallie, G DeBoer, G Haddad, N Ikegaki, J Dimitroulakos, H Yeger and V Ling
Division of Hematology-Oncology and Immunology, Department of Pediatrics,The Hospital for Sick Children, 555 University Ave., Toronto, Ontario, M5G 1X8 Canada. hlschan@resunix.ri.sickkids.on.ca

About half of nonlocalized neuroblastomas have MYCN gene amplification and usually progress rapidly, but the half without such amplification also do poorly, albeit progressing more slowly. We hypothesize that overexpression of MYCN protein can occur without gene amplification and that this expression reliably predicts the prognosis of neuroblastoma. To determine whether MYCN expression correlated with outcome, we assayed MYCN protein immunohistochemically in 180 archival pretreatment and posttreatment samples and stratified the 57 conventionally treated stage IVS, III, and IV patients by these conventional prognostic factors: stage, age, serum ferritin, Shimada histology, urinary catecholamine ratio, and MYCN gene status. At a median follow-up of >/=6.8 years, we found in patients with known MYCN gene status that the 23 of 37 without gene amplification fared no better than the 14 of 37 with gene amplification (P = 0.35 and 0.21, comparing relapse-free and survival rates). Conversely, in patients without MYCN gene amplification, 9 of 23 were found to overexpress MYCN protein pretreatment, and they did worse than the 14 of 23 without detectable MYCN protein (P = 0.0016 and 0.022, comparing relapse-free and survival rates). Furthermore, MYCN protein expression was prognostic without (P = 0.00001) and with (P = 0.0007) stratifying all 57 patients by MYCN gene status, each conventional prognostic factor (P ranging from 0.00001-0.013), or simultaneously by the two most important factors, stage and age (P = 0.00076). We conclude that overexpression of MYCN protein without gene amplification correlated significantly with the clinical behavior of neuroblastoma and predicted outcome independently of other prognostic factors. This strongly supports the hypothesis that expression of the MYCN oncogene is critical for progression of neuroblastoma.

This article has been cited by other articles:

				C. Stock, E. Bozsaky, F. Watzinger, U. Poetschger, L. Orel, T. Lion, A. Kowalska, and P. F. Ambros Genes Proximal and Distal to MYCN Are Highly Expressed in Human Neuroblastoma as Visualized by Comparative Expressed Sequence Hybridization Am. J. Pathol., January 1, 2008; 172(1): 203 - 214. [Abstract] [Full Text] [PDF]

				X. X. Tang, H. Zhao, B. Kung, D. Y. Kim, S. L. Hicks, S. L. Cohn, N.-K. Cheung, R. C. Seeger, A. E. Evans, and N. Ikegaki The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma. Cancer Res., March 1, 2006; 66(5): 2826 - 2833. [Abstract] [Full Text] [PDF]

				E. Ciani, S. Severi, A. Contestabile, R. Bartesaghi, and A. Contestabile Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation J. Cell Sci., September 15, 2004; 117(20): 4727 - 4737. [Abstract] [Full Text] [PDF]

				L. M. Hansford, W. D. Thomas, J. M. Keating, C. A. Burkhart, A. E. Peaston, M. D. Norris, M. Haber, P. J. Armati, W. A. Weiss, and G. M. Marshall Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification PNAS, August 24, 2004; 101(34): 12664 - 12669. [Abstract] [Full Text] [PDF]

				M. Alaminos, J. Mora, N.-K. V. Cheung, A. Smith, J. Qin, L. Chen, and W. L. Gerald Genome-wide Analysis of Gene Expression Associated with MYCN in Human Neuroblastoma Cancer Res., August 1, 2003; 63(15): 4538 - 4546. [Abstract] [Full Text] [PDF]

				J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn Advances in the Diagnosis and Treatment of Neuroblastoma Oncologist, June 1, 2003; 8(3): 278 - 292. [Abstract] [Full Text] [PDF]

				M. Krams, H.-J. Heidebrecht, B. Hero, F. Berthold, D. Harms, R. Parwaresch, and P. Rudolph repp86 Expression and Outcome in Patients With Neuroblastoma J. Clin. Oncol., May 1, 2003; 21(9): 1810 - 1818. [Abstract] [Full Text] [PDF]

				A. Lasorella, R. Boldrini, C. Dominici, A. Donfrancesco, Y. Yokota, A. Inserra, and A. Iavarone Id2 Is Critical for Cellular Proliferation and Is the Oncogenic Effector of N-Myc in Human Neuroblastoma Cancer Res., January 1, 2002; 62(1): 301 - 306. [Abstract] [Full Text] [PDF]

				L. Fan, J. Iyer, S. Zhu, K. K. Frick, R. K. Wada, A. E. Eskenazi, P. E. Berg, N. Ikegaki, R. H. Kennett, and C. N. Frantz Inhibition of N-myc Expression and Induction of Apoptosis by Iron Chelation in Human Neuroblastoma Cells Cancer Res., February 1, 2001; 61(3): 1073 - 1079. [Abstract] [Full Text]

				K. K. Matthay MYCN Expression in Neuroblastoma: A Mixed Message? J. Clin. Oncol., November 1, 2000; 18(21): 3591 - 3594. [Full Text] [PDF]

				S. L. Cohn, W. B. London, D. Huang, H. M. Katzenstein, H. R. Salwen, T. Reinhart, J. Madafiglio, G. M. Marshall, M. D. Norris, and M. Haber MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN J. Clin. Oncol., November 1, 2000; 18(21): 3604 - 3613. [Abstract] [Full Text] [PDF]

				A. K. Sarkar and J. G. Nuchtern Lysis of MYCN-amplified Neuroblastoma Cells by MYCN Peptide-specific Cytotoxic T Lymphocytes Cancer Res., April 1, 2000; 60(7): 1908 - 1913. [Abstract] [Full Text]

				A. Misawa, H. Hosoi, A. Arimoto, T. Shikata, S. Akioka, T. Matsumura, P. J. Houghton, and T. Sawada N-Myc Induction Stimulated by Insulin-like Growth Factor I through Mitogen-activated Protein Kinase Signaling Pathway in Human Neuroblastoma Cells Cancer Res., January 1, 2000; 60(1): 64 - 69. [Abstract] [Full Text]

				C. F. Manohar, M. L. Short, A. Nguyen, N. N. Nguyen, D. Chagnovich, Q. Yang, and S. L. Cohn HuD, a Neuronal-specific RNA-binding Protein, Increases the in Vivo Stability of MYCN RNA J. Biol. Chem., January 11, 2002; 277(3): 1967 - 1973. [Abstract] [Full Text] [PDF]